- Insider Monkey•3 days agoValeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) Collapse
Buyout talks between Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) that would have resulted in the sale of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), which Valeant owns, have broken down. The negotiations could be revived, but Valeant doesn’t seem keen on resuming talks to sell its Salix business as it has already […]
- CNBC•4 days ago
The talks with Takeda Pharmaceutical have ended amid a disagreement over the price and other matters, CNBC can confirm.
- Reuters•4 days ago
Takeda Pharmaceutical Co Ltd's negotiations to acquire Valeant Pharmaceuticals International Inc's Salix stomach-drug business have stalled over price disagreements, people familiar with the matter said on Wednesday. Shares of Valeant were down more than 8 percent at $15.71 on Wednesday after the Wall Street Journal reported that the talks had broken down. A deal for Salix would help Valeant trim the large debt pile it accumulated through aggressive acquisitions.
TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||20.37 - 20.72|
|52 Week Range||20.15 - 25.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.17|
|Dividend & Yield||0.87 (4.23%)|
|1y Target Est||N/A|